International Journal of Medical Sciences

Impact factor
2.399

22 October 2017

ISSN 1449-1907 News feeds of published articles

My Manuscript | My Account

Journal of Genomics now in PubMed/PubMed Central. Submit manuscript...

Journal of Biomedicinenew

Theranostics

Journal of Cancer

Oncomedicine

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2008; 5(2):100-105. doi:10.7150/ijms.5.100

Research Paper

MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER

Armelle Dufresne1, Xavier Pivot2, Christophe Tournigand3, Thomas Facchini4, Thierry Alweeg5, Loic Chaigneau2, Aimery De Gramont3

1. University Hospital E. Herriot, Lyon, France
2. University Hospital J. Minjoz, Besancon, France
3. University Hospital Sain Antoine, Paris, France
4. Cancer Center, Reims, France
5. Cancer Center, Dijon, France

Abstract

The present study was conducted in patients with metastatic breast cancer. Its aim was to identify the factors which influence progression -free survival (PFS) and overall survival (OS) after the first line of chemotherapy in patients with positive tumour hormone receptor status. The patients with early disease progression during first-line chemotherapy were not included. In total, 560 patients who achieved a stable disease or a response to first-line chemotherapy were studied. The factors identified to improve the duration of PFS or OS in multivariate analysis were: number of metastatic sites (p = .01; p = .01), metastatic sites (p = .02; p = .04), Disease free interval (p = .001; p < .0001), previous hormonal therapy (p = .03; p = ns), response to first line chemotherapy (p < .0001; p = 0.0001) and an administration of maintenance hormonal therapy (p < .0001; p = .001). The major impact obtained by maintenance hormonal treatment after first-line chemotherapy in this study seems to indicate that this strategy should be recommended in patients with an ER or PgR positive tumour.

Keywords: Breast cancer, maintenance treatment, chemotherapy, Metastatic, hormonotherapy.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Dufresne A, Pivot X, Tournigand C, Facchini T, Alweeg T, Chaigneau L, De Gramont A. MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER. Int J Med Sci 2008; 5(2):100-105. doi:10.7150/ijms.5.100. Available from http://www.medsci.org/v05p0100.htm